Cargando…
T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection
Humoral responses are essential for the protective efficacy of most Ebola virus (EBOV) candidate vaccines; however, the in vivo development of protective anti-EBOV B-cell responses is poorly defined. Here, by using the virus-like particle (VLP) as a model antigen, we demonstrate that humoral respons...
Autores principales: | Cooper, Christopher L, Martins, Karen A, Stronsky, Sabrina M, Langan, David P, Steffens, Jesse, Van Tongeren, Sean, Bavari, Sina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520308/ https://www.ncbi.nlm.nih.gov/pubmed/28588288 http://dx.doi.org/10.1038/emi.2017.31 |
Ejemplares similares
-
A thermostable, chromatographically purified Ebola nano-VLP vaccine
por: Carra, John H, et al.
Publicado: (2015) -
Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity
por: Martins, Karen A.O., et al.
Publicado: (2015) -
Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation
por: Martins, Karen A. O., et al.
Publicado: (2014) -
Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)
por: Dye, John M., et al.
Publicado: (2016) -
Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
por: Warren, Travis K., et al.
Publicado: (2021)